Question from Deputy Ken O'Flynn - PQ 10654-26
Deputy O'Flynn asked whether the HSE has completed a formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked whether the HSE has completed a formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management.
Deputy Brabazon asked about the waiting list to see a speech and language therapist for a first appointment at Tonlegee Primary Care Centre Dublin 5.
Deputy Cullinane asked about pathologist posts at University Hospital Waterford. Read the HSE response.
Deputy O'Flynn asked about the number of residential properties currently owned by the HSE which are vacant. Read the HSE response.
Deputy O'Flynn asked about the factors affecting the timely reuse or disposal of vacant residential properties owned by the HSE. Read the HSE response.
Deputy O'Flynn asked about the use of GLP-1 receptor agonist medicines for obesity or weight management. Read the HSE response.
Deputy O'Flynn asked about the annual cost of maintaining vacant residential properties owned by the HSE. Read the HSE response.
Deputy O'Flynn asked about the policy framework governing the retention, disposal, or repurposing of vacant residential properties owned by the HSE.
Deputy Clarke asked when the current pause in recruitment of physician associates is expected to be lifted. Read the HSE response.
Deputy Byrne asked about the ambulance response performance for Clinical Status 1 incidents in the North East region. Read the HSE response.